NEW YORK (GenomeWeb) - Veracyte announced after the close of the market Thursday a 25 percent rise in third quarter revenues amid increased demand for the company's Afirma gene expression classifier (GEC) test.

For the three-month period ended Sept. 30, Veracyte's revenues increased to $12.3 million from $9.8 million in the year ago period, but missed analysts' consensus estimate of $12.7 million. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.